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abstract
PURPOSE We sought to investigate clinical outcomes of relapsed medulloblastoma and to compare molecular
features between patient-matched diagnostic and relapsed tumors.
METHODS Children and infants enrolled on either SJMB03 (NCT00085202) or SJYC07 (NCT00602667) trials
who experienced medulloblastoma relapse were analyzed for clinical outcomes, including anatomic and
temporal patterns of relapse and postrelapse survival. A largely independent, paired molecular cohort was
analyzed by DNA methylation array and next-generation sequencing.
RESULTS A total of 72 of 329 (22%) SJMB03 and 52 of 79 (66%) SJYC07 patients experienced relapse with
significant representation of Group 3 and wingless tumors. Althoughmost patients exhibited some distal disease
(79%), 38% of patients with sonic hedgehog tumors experienced isolated local relapse. Time to relapse and
postrelapse survival varied by molecular subgroup with longer latencies for patients with Group 4 tumors.
Postrelapse radiation therapy among previously nonirradiated SJYC07 patients was associated with long-term
survival. Reirradiation was only temporizing for SJMB03 patients. Among 127 patients with patient-matched
tumor pairs, 9 (7%) experienced subsequent nonmedulloblastoma CNS malignancies. Subgroup (96%) and
subtype (80%) stabilities were largely maintained among the remainder. Rare subgroup divergence was ob-
served from Group 4 to Group 3 tumors, which is coincident with genetic alterations involvingMYC,MYCN, and
FBXW7. Subgroup-specific patterns of alteration were identified for driver genes and chromosome arms.
CONCLUSION Clinical behavior of relapsed medulloblastoma must be contextualized in terms of up-front
therapies and molecular classifications. Group 4 tumors exhibit slower biological progression. Utility of radi-
ation at relapse is dependent on patient age and prior treatments. Degree and patterns of molecular con-
servation at relapse vary by subgroup. Relapse tissue enables verification of molecular targets and identification
of occult secondary malignancies.
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INTRODUCTION
Medulloblastoma relapse represents a key determinant
of cancer-relatedmortality in the pediatric population.1,2
Multimodal therapy that incorporates maximal surgical
resection with craniospinal irradiation (CSI; children
older than 3 years) and chemotherapy has driven
5-year overall survival rates to 80%-85% for average-
risk disease and 60%-70% for high-risk disease.3,4
Nevertheless, treatment failure and relapse occur in
up to one-third of patients and confers abysmal prog-
nosis, with only approximately 10% of patients surviv-
ing beyond 5 years postrelapse.5-7 Relapsed disease
thus remains extremely refractory to existing thera-
pies, whereas rare survivors often experience serious
toxicity and devastating neurocognitive sequalae.8,9
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medulloblastoma exists, salvage therapies, including
conventional and targeted agents, have largely failed to
confer durable survival benefit.10,11 A deeper clinical and
biological understanding of medulloblastoma recurrence is
needed for the design and interpretation of next-generation
clinical trials for relapsed disease.
Although extensive genomic characterization of medullo-
blastoma has identified four biologically and clinically distinct
subgroups (wingless [WNT], sonic hedgehog [SHH], Group 3,
and Group 4), most studies have relied on diagnostic samples
that have not been exposed to tumor-directed therapies.12
Comparative molecular studies of diagnostic versus relapsed
medulloblastoma have suggested divergent clonal selection,
leading to emergence of specific molecular alterations at
relapse in the context of subgroup conservation.13-16 However,
the generalizability of such findings is diminished by relatively
modest cohort sizes and employment of different molecular
assays. Additionally, exclusion of secondary CNS malignan-
cies subsequent to medulloblastoma therapy, particularly
high-grade gliomas, requires robust classification methods to
prevent inadvertent cross-entity comparisons and may rep-
resent a key limitation of previous comparative studies.17,18
Multiple recent studies have leveraged DNA methylation
profiling to describe additional intertumoral heterogeneity
within the core medulloblastoma subgroups.19-21 These
subtypes, primarily defined among SHH (a, b, g, and d)
and Groups 3 and 4 (I-VIII) tumors, have distinctive genetic
and clinical features.22,23 Furthermore, subtype-defined
risk paradigms are an active area of investigation. However,
contextualization of these subtypes in relapsed disease
and assessment of conservation at relapse are lacking.
In this study, subgroup-specific clinical behavior of relapsed
medulloblastoma is described for patients enrolled on two,
multi-institutional, risk-adapted clinical trials. A largely in-
dependent, paired molecular cohort composed of patient-
matched diagnostic and relapse tumors is investigated to
determine the molecular features of medulloblastoma re-




Study populations are summarized in the Data Supplement
(online only). Eligible patients with relapsed medulloblas-
toma from two multi-institutional, risk-adapted clinical tri-
als, SJMB03 (NCT00085202; Gajjar et al24 and SJYC07
(NCT00602667),23 were included (Appendix Table A1,
online only; Data Supplement). Patients with a clinical
diagnosis of nonmedulloblastoma subsequent malignancy
were excluded. Given the differing eligibility criteria, risk
stratifications, and treatment protocols between the trials,
patients from each trial were analyzed separately for clinical
outcomes based onmolecular features garnered from primary
tumor specimens. A largely independent, paired molecular
cohort of 127 patients with formalin-fixed paraffin-embedded
(FFPE) or frozen tissue specimens available from both their
histopathologically diagnosed primary medulloblastoma and
relapse or subsequent tumors was also assembled (Appendix
Table A2, online only; Data Supplement). Comparative mo-
lecular analyses were performed among the paired molecular
cohort using patient-matched primary and relapsed tumor
specimens.
Tumor Molecular Profiling
Tumor specimens were analyzed using Infinium Methyla-
tion EPIC or 450K BeadChip arrays (Illumina, San Diego,
CA) from either freshly frozen or FFPE tissue (Data Sup-
plement). Medulloblastoma subgroup and subtype pre-
dictions were determined using DNA methylation–based
classification of CNS tumors (MolecularNeuropathology,
Heidelberg, Germany, version 11b4) and trained random
forest predictions.18 Genome-wide DNA copy number al-
terations were inferred from DNA methylation arrays using
the Conumee R package.
Next-generation (whole-exome or targeted gene panel)
sequencing was performed on tumor samples with suffi-
cient material available. Additional details regarding bio-
informatic processing are given in the Appendix Methods
(Data Supplement). Genomic datasets included in this
CONTEXT
Key Objective
To determine the clinical outcomes and molecular features of relapsed medulloblastoma.
Knowledge Generated
Time to relapse and postrelapse survival are associated with subgroup with Group 4 tumors exhibiting slower biological
progression. Utility of radiation therapy at relapse depends on age and previous therapies. Most relapses exhibit
concordant subgroup classifications, except in the cases of occult secondary malignancies or rare divergence from group
4 to group 3. Driver gene and chromosome arm alteration patterns vary according to molecular subgroup.
Relevance
Future trials for relapsed medulloblastoma must be contextualized by molecular subgroup and up-front therapies. Relapse
tissue should be acquired and used for confirmation of diagnosis and verification of molecular targets.
2 © 2021 by American Society of Clinical Oncology
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study can be freely explored using the online St Jude Cloud
pediatric genomic data resource.25
Statistical Analysis
Time-to-event analyses were performed using Kaplan-
Meier methods with log-rank tests. Hazard ratios (HRs)
with associated 95% CIs and P values were computed
using Cox regression. Distributions of categorical variables
were compared using Fisher’s exact or chi-square test.
Multiple testing correction was performed using false dis-
covery rate. Statistical analyses were performed using R
version 3.5.1 and are further detailed in the Appendix
Methods (Data Supplement).
RESULTS
Incidence of Relapsed Disease
An overview of inclusion criteria, risk stratifications, and
treatment protocols for SJMB03 and SJYC07 is shown in
Figure 1A. A total of 72 of 329 (22%) patients from
SJMB03 and 52 of 79 from SJYC07 (66%) relapsed (Fig
1B). Appendix Table A1 summarizes the demographic
and clinical characteristics of relapsed patients from
each trial according to molecular subgroup. Notably,
WNT subgroup relapsed medulloblastomas were absent
in both trials. Distributions of subgroups across clinical
trial risk groups for relapsed patients are shown in
Figure 1C.
Subgroup distribution between relapsed and nonrelapsed
patients was not uniform in either SJMB03 (P 5 .0019,
chi-square test) or SJYC07 (P 5 .00083, chi-square test;
Fig 1B). Compared with Group 3 tumors, Group 4 tumors
had a lower relapse rate in SJMB03 (odds ratio [OR], 0.31;
95% CI, 0.16 to 0.61), whereas SHH tumors had a lower
relapse rate in SJYC07 (OR, 0.08; 95% CI, 0.01 to 0.33).
The distribution of novel subtypes19,20,22,23 between re-
lapsed and nonrelapsed patients was not uniform for
Groups 3 and 4 subtypes in SJMB03 (P , .0001, chi-
square test) or SHH subtypes in SJYC07 (P 5 .0058, chi-
square test; Data Supplement). Proportions of relapsed
patients between SJMB03 and SJYC07 differed for novel
Groups 3 and 4 subtypes IV (P, .0001, Fisher’s exact test)
and VII (P , .0001, Fisher’s exact test).
Time to Relapse
The median time to relapse was 1.64 years (interquartile
range [IQR], 0.91-3.03) for SJMB03 and 0.72 year (IQR,
0.47-1.00) for SJYC07 (Data Supplement). For SJMB03,
time to relapse varied by molecular subgroup (P5 .00087,
log-rank test) with a median time to relapse for patients with
Group 4 tumor of 2.79 years (IQR, 1.99-3.64) compared
with 0.91 year (IQR, 0.68-1.37) for Group 3 (HR, 3.01;
95% CI, 1.67 to 5.41) and 1.23 years (IQR, 0.96-2.34) for
patients with SHH (HR, 2.41; 95%CI, 1.20 to 4.81; Fig 1D).
For SJYC07, time to relapse also varied by molecular
subgroup (P 5 .039, log-rank test), largely driven by
difference between Group 4 and Group 3 tumors (HR,
2.74; 95% CI, 1.14 to 6.60; Fig 1E). Clinical risk group was
a significant covariate for time to relapse only among pa-
tients with Group 4 tumor in SJMB03 (Data Supplement).
Time to relapse according to novel SHH and Groups 3 and
4 subtypes is shown in Data Supplement.
Anatomic Patterns of Relapse
Relapse occurred with a distant component in 57 (79%)
SJMB03 patients (Fig 1F) and 41 (79%) SJYC07 patients
(Fig 1G). Of patients with SHH tumors, 43% in SJMB03
and 35% in SJYC07 presented with isolated local relapse
compared with only 14% (P5 .028, Fisher’s exact test) and
10% (P 5 .067, Fisher’s exact test) of non-SHH tumors,
respectively (Figs 1F and 1G). Distant relapses were sig-
nificantly associated with shorter time to relapse only for
Group 4 tumors in SJMB03 (HR, 5.08; 95% CI, 1.14 to
22.6) and SHH tumors in SJYC07 (HR, 3.48; 95% CI, 1.07
to 11.3; Data Supplement).
Survival After Relapse
At data cutoff, seven relapsed patients (10%) from SJMB03
and 24 (46%) from SJYC07 were alive. The median
postrelapse survival (PRS) was 1.14 years (IQR, 0.30-2.36)
for SJMB03 and 2.12 (IQR, 0.39-NA) for SJYC07 (Data
Supplement). Clinical trial risk group was not significantly
associated with PRS for SJMB03 (P5 .43, log-rank test) or
SJYC07 (P 5 .099, log-rank test; Data Supplement).
For SJMB03, PRS time varied by molecular subgroup (P5
.016, log-rank) with the median PRS time for patients with
Group 4 tumors of 2.27 years (IQR, 1.19-3.89) compared
with 0.44 year (IQR, 0.29-1.29) for patients with Group 3
tumors (HR, 2.39; 95% CI, 1.29 to 4.42) and 1.06 years
(IQR, 0.27-1.88) for patients with SHH tumors (HR, 1.90;
95%CI, 0.94 to 3.83; Fig 2A). For SJYC07, PRS did not vary
significantly by molecular subgroup (P5 .88, log-rank test;
Fig 2B). Time to relapse was significantly associated with
PRS for SJMB03 (HR, 0.65; 95% CI, 0.52 to 0.82) but not
for SJYC07 (HR, 0.53; 95% CI, 0.23 to 1.23). Notably, the
association of time to relapse and PRS for SJMB03
remained significant with subgroup and clinical trial risk
group as additional covariates (HR, 0.67; 95% CI, 0.50 to
0.90). PRS according to novel SHH and Groups 3 and 4
subtypes is shown in the Data Supplement.
Twenty-five (35%) relapsed SJMB03 patients (one patient
missing data) and 30 (58%) SJYC07 patients received
radiation after relapse. For SJMB03 patients, a transient
PRS benefit (P5 .032, log-rank test; Fig 2C) was observed
with additional radiation after relapse (HR, 0.56; 95% CI,
0.33 to 0.96). For SJYC07 patients, postrelapse CSI (me-
dian, 36.0 Gy) was significantly associated with long-term
survival (P , .0001, log-rank test; Fig 2D), particularly for
patients with SHH (HR, 0.04; 95% CI, 0.01 to 0.37) and
Group 3 tumors (HR, 0.27; 95% CI, 0.08 to 0.85) (Data
Supplement).
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SJMB03 Time to Relapse by MB Subgroup (n = 74 patients)
Log-rank P = .00087
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Group 3: 0.91 yrs
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SJYC07 Time to Relapse by MB Subgroup (n = 52 patients)
Log-rank P = .039
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FIG 1. Relapse patterns for SJMB03 and SJYC07 patients with medulloblastoma. (A) Overview of trial designs and risk stratifications. (B) Apparent
relapse rates by medulloblastoma subgroup per trial. (C) Medulloblastoma subgroup distributions per trial risk stratifications. Time to relapse by
subgroup for SJMB03 patients (D) and SJYC07 patients (E). Anatomic patterns of relapse per subgroup for SJMB03 (F) and SJYC07 (G) patients. CSI,
craniospinal irradiation; DNMB, desmoplastic nodular medulloblastoma; GTR, gross total resection; HDMTX, high-dose methotrexate; MB, medul-
loblastoma; RT, radiation therapy; SHH, sonic hedgehog; TTR, time to relapse; UC, unclassified; VCR, vincristine; WNT, wingless.
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Patient-Matched Molecular Landscapes
Given the rarity of tissue availability from relapsed medul-
loblastoma and with only seven patients from each trial with
relapse tissue available, a large multi-institutional, paired
molecular cohort of 127 patient-matched diagnostic and re-
lapsed tumors was assembled (Fig 3A; Appendix Table A2;
Data Supplement). Sufficient tissue for DNA methylation
profiling was required for inclusion, and whole-exome or
targeted panel sequencing data were available for both
patient-matched samples in 50% (64 of 127) of the paired
molecular cohort (Fig 3B). DNA methylation classification
identified nine relapse cases (7%) as nonmedulloblastoma
subsequent tumors within the paired molecular cohort
(Fig 3C; Data Supplement).18
Molecular Subgroups and Subtypes
Among 118 patients with molecularly confirmed re-
lapsed medulloblastoma, diagnostic tumors were clas-
sified by methylation as WNT in 1 (1%), SHH in 48
(41%), Group 3 in 22 (19%), and Group 4 in 46 (39%).
Medulloblastoma subgroup was conserved at relapse in
113 patients (96%) with divergence observed in a total of
five patients between Groups 3 and 4 tumors. Novel
molecular subtypes within SHH and Groups 3 and 4
tumors were conserved at relapse in 80% of patients
(Figs 3D and 3E).19,20
To assess the degree of molecular conservation between
patient-matched diagnostic and relapsed tumors, muta-
tions and copy number alterations of curated medullo-
blastoma driver genes and chromosomal arms were
analyzed (Fig 4A; Data Supplement).19 Subgroup desig-
nation for paired patient-matched cases was based on
subgroup at diagnosis.
Driver Gene Alteration Patterns
The distribution and pattern of driver gene alterations by
subgroup are shown in Figure 4B. Subgroup was associated
with a significant difference in conservation pattern of driver
gene alterations, largely driven by biases in SHH, which were
predominantly conserved (P , .0001, analysis of variance).
The median number of discordant driver gene alterations
between patient-matched tumors was one with no differ-
ence between subgroups (P 5 .10, Kruskal-Wallis test;
Data Supplement). A total of 29% of cases had completely
conserved driver gene alterations with no statistical differ-
ence between subgroups (P 5 .29, chi-square test). Within
subgroups, the number of discordant copy number varia-
tions or mutations was not significantly associated with age
at diagnosis, time to relapse, or recurrence pattern (Data
Supplement).
The incidence of shared driver gene alterations was 52% in
SHH, 36% in Group 3, and 37% in Group 4 tumors (Figs 4A
F
Anatomic Patterns of Relapse for SJMB03
Local only versus Distant component Chi-square P = .058
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and 4B). Notable shared driver gene alterations included
those affecting PTCH1 (10 of 12, 88% shared) and DDX3X
(6 of 7, 86%) in SHH tumors. The incidence of relapse-
specific driver gene alterations was 29% in SHH, 57%
in Group 3, and 40% in Group 4 tumors. Additionally,
numerous low incidence relapse-specific alterations, par-
ticularly among chromatin modifiers (eg, CREBBP and
SMARCA4) and DNA repair machinery (eg, BRCA2), were
observed across subgroups. Primary-specific driver gene
alterations, such as focal CDK6 amplification in one primary
SHH tumor and one primary Group 4 tumor, were rare and
comprised the minority in observed patterns of conserva-
tion and divergence.
Driver genes with increased odds of alteration in relapsed
patients were identified using primary tumor molecular data
available for the clinical trial cohorts (Data Supplement).
Conservation pattern of such alterations, including TP53
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FIG 2. Postrelapse outcomes for SJMB03 and SJYC07 patients with medulloblastoma. PRS by subgroup for SJMB03 (A) and SJYC07 (B) patients.
Postrelapse survival by receipt of radiation therapy after relapse for SJMB03 (C) and SJYC07 (D) patients. MB, medulloblastoma; OS, overall survival;
PRS, postrelapse survival; RT, radiation therapy; SHH, sonic hedgehog.
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BA
Inclusion Criteria:
Patients with histopathologically diagnosed MB
Sufficient tissue available for both primary and subequent tumors
131 patients
271 tumors
1 primary tumor unclassifiable
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FIG 3. Overview of patient-matchedmolecular cohort. (A) Flowchart describing assembly of pairedmolecular cohort composed of patients with truly
relapsed medulloblastomas and those with other subsequent CNS malignancies. (B) Methylation and next-generation sequencing data availability
for each arm of the paired molecular cohort. (C) Subgroup and entity classification of patient-matched tissue from diagnosis and relapse. Novel
Groups 3 and 4 (D) and SHH (E) subtype classifications of patient-matched tissue from diagnosis and relapse. EWS, Ewing sarcoma; HGG,
high-grade glioma; iSHH, infant SHH; MB, medulloblastoma; NGS, next-generation sequencing; SHH, sonic hedgehog; WES, whole-exome
sequencing; WNT, wingless.
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%92%91 52% 57%7% %04%32%63 37%
Subgroup Versus Alteration Pattern P < .001
Pattern of alteration: Relapse onlyPrimary onlyShared
FIG 4. Molecular landscape of relapsedmedulloblastoma. (A) Oncoprint depicting patient characteristics, driver gene alterations, and chromosomal
copy number variation for patient-matched tumor pairs with available next-generation sequencing (n 5 57 patients). (B) Compartment-specific
patterns of driver gene alterations by molecular subgroup. (C) Genomic track of chromosome 2 depicting alteration patterns observed forMYCN. (D)
Compartment-specific patterns of chromosome arm copy number variation by molecular subgroup for patient-matched tumor pairs (n 5 107
patients). Genomic tracks depicting alteration patterns of chromosome 17 (E) and chromosome 10 (F). CNV, copy number variation; G3, Group 3;
G4, Group 4; MB, medulloblastoma; SHH, sonic hedgehog; SNV, single nucleotide variant; WES, whole-exome sequencing; WNT, wingless.
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FIG 4. (Continued).
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queried in the paired molecular cohort (Figs 4A and 4B;
Data Supplement).
Among relapsed cases in the paired molecular cohort,
mutations in TP53 were restricted to SHH tumors (P 5
.0080, Fisher’s exact test) and were relapse-specific in
two (40%) and shared in three (60%) patients (Figs 4A
and 4B). Predominantly occurring within Group 3 tumors
(P 5 .00049, Fisher’s exact test), amplifications of MYC
were identified as shared in five (63%, including one
Group 4), primary-specific in one (13%), and relapse-
specific in two (25%, including one SHH) patients (Data
Supplement). Amplifications of MYCN were identified
among seven patients with SHH and five patients with
Group 4 tumors with 42% occurring as shared, 25% as
primary-specific, and 33% as relapse-specific with no sta-
tistical difference in alteration pattern between subgroups
(P 5 .77, chi-square test; Figs 4A-4C; Data Supplement).
Of 34 driver genes with identified alterations, 15 (44%)
are theoretically actionable and occurred in 72% of pa-
tients (Data Supplement). Of theoretically actionable al-
terations, 46% were shared between patient-matched
tumors, whereas 33% were relapse-specific and 21% were
primary-specific.
Chromosomal Alteration Patterns
Genome-wide distribution and patterns of chromosomal
arm alterations were also investigated (Figs 4A, 4D, and 4E,
Data Supplement). The incidence of shared chromosome
arm alterations was 42% for SHH, 61% for Group 3, and
58% for Group 4 tumors (Fig 4D). Subgroup was associated
with a significant difference in the pattern of chromosome
arm alterations, largely driven by biases in Group 3 tumors,
which were predominantly conserved (P5 .0047, analysis
of variance). The median number of discordant chromo-
some arms between patient-matched tumors was two (IQR,
0-5) with no difference between subgroups (P 5 .10,
Kruskal-Wallis test; Data Supplement). Thirty-three percent
of patients had completely conserved cytogenetic land-
scapes with no statistical difference between subgroups
(P 5 .13, chi-square test). Chromosome arms did not
exhibit uniform alteration patterns (asterisks in Fig 4D, false
discovery adjusted P , .1, chi-square test), as exemplified
by highly conserved isochromosome 17q in Group 3 and
Group 4 tumors (Fig 4E). Additionally, frequent relapse-
specific losses of chromosomes 10q (31%) and 17p (46%)
were recognized in SHH tumors (Fig 4F).
Subgroup and Subtype Divergence at Relapse
Subgroup divergence at relapse was observed in five of 118
cases (4%). Four patients diagnosed with high-confidence
Group 4 tumors (median classification score, 0.97; IQR,
0.92-0.99) developed relapse tumors that were classified
as high-confidence Group 3 tumor (median classification
score, 0.92; IQR, 0.88-0.97; Fig 5A). One patient was
diagnosed with a Group 3 tumor (classification score, 0.96)
and experienced relapse with a Group 4 tumor of inter-
mediate classification score (Group 4 classification score,
0.53; Group 3 classification score, 0.47).
All cases of Group 4 to Group 3 switching exhibited dis-
cordant subtype classifications (Data Supplement). Two
cases with primary subtype VII tumors diverged to subtypes
II and V at relapse. Other two cases diverged to subtype
III from subtypes VI and VIII. Relapse-specific genetic al-
terations affecting MYC, MYCN, and FBXW7 were also
observed in such subgroup-switching cases (Fig 5B). An
exemplary case is depicted in Figures 5C and 5D. Notably,
the single Group 3 to Group 4 switching case was classified
as subtype V at both diagnosis and relapse.
Subtype divergence occurred at similar rates among both
SHH (17%) and Groups 3 and 4 tumors (22%; P 5 .64,
Fisher’s exact test). No specific pattern of subtype inho-
mogeneity was identified (Data Supplement; P 5 .34,
Stuart-Maxwell test). Notably, only the presence of MYC
amplification or chromosome 2p gain in relapsed tumors
was significantly associated with Groups 3 and 4 subtype
divergence (P , .05, Fisher’s exact test; Fig 4A; Data
Supplement).
Nonmedulloblastoma Subsequent Tumors
Nonmedulloblastoma subsequent tumors were identified in
nine (7%) patients (Fig 3A). High-grade gliomas accounted
for eight (89%) such cases (Fig 6A). The median age of
medulloblastoma diagnosis for these patients was 10.4
years (IQR, 9.2-10.8), and seven patients received radio-
therapy for medulloblastoma (radiation therapy treatment
status for one patient was unknown). The median interval
from initial medulloblastoma to diagnosis of subsequent
high-grade glioma was 3.77 years (IQR, 2.73-4.38).
Molecular alterations observed in subsequent tumors are
depicted in Figure 6B. Recurrent focal CDKN2A and/or
CDKN2B homozygous deletions and MET amplifications
were identified almost exclusively among subsequent gli-
omas (Data Supplement). No strong overlap of chromo-
some arm alterations was identified between diagnostic
medulloblastomas and subsequent high-grade gliomas
(Fig 6C). An exemplary case of subsequent high-grade
glioma following Group 4 medulloblastoma is depicted in
Figures 6D and 6E.
DISCUSSION
Although relapse rates in SJMB03 (22%) and SJYC07
(66%) suggest the critical role of up-front CSI in disease
control, the temporal patterns of relapse highlight the
slower biological progression of Group 4 tumors. Patients
not previously treated with CSI (SJYC07) largely relapsed
on or shortly after therapy, irrespective of subgroup. Al-
though the aggressive nature of Group 3 tumors is high-
lighted in both trials, the different relapse rates observed
for tumors assigned to Groups 3 and 4 subtypes IV and
10 © 2021 by American Society of Clinical Oncology
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VII between trials motivate exploration of tailored treat-
ment strategies driven by molecular subtype. Additionally, the
propensity for local relapse among a subset of SHH tumors
aligns with previous findings.13 Although our ability to discern
subgroup-specific anatomic patterns of relapse might have
been limited by cohort size, the high proportion of medullo-
blastomas with distant relapse highlights the dire need for
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MB-24 Diagnostic MYCN FISH
FIG 5. Subgroup divergence at medulloblastoma relapse. (A) Scatterplot depicting Group 3 and 4 classification scores for patients (n5 5) with divergent
subgroup at relapse. (B) Oncoprint depicting alterations among patients with diagnostic group 4 tumors experiencing Group 3 relapse. A patient with
primary Group 4 primary tumor (C) who experienced relapse with a Group 3 tumor (D) coincident with focal amplification ofMYCN. G3, Group 3; G4, Group
4; MB, medulloblastoma; NGS, next-generation sequencing; SNV, single nucleotide variant.
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Salvage rates of relapsed medulloblastoma are low and
highly dependent on previous radiation therapy.11,26
Standardized protocols for salvage therapy are lacking,
and studies describing potential survival benefits of vari-
ous therapies are plagued by small numbers and further
confounded by subgroup heterogeneity.27 In this study,
radiation therapy after relapse was associated with durable
long-term survival in a subset of radiation-naive patients
(SJYC07), irrespective of subgroup. However, young pa-
tients, particularly infants, will benefit from continuous
D
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FIG 6. High-grade gliomas subsequent to primary medulloblastoma. (A) Classification scores of primary medulloblastomas and subsequent high-grade
gliomas. (B) Oncoprint depicting patient characteristics and driver gene alterations for patient-matched tumor pairs with available next-generation sequencing
(n5 6 patients). (C) Compartment-specific patterns of chromosome arm copy number variation for patient-matched tumor pairs (n5 8 patients). A patient
with primary Group 4 tumor (D) who experienced subsequent high-grade glioma (E) in the local tumor bed. MRI, magnetic resonance imaging. HGG,
high-grade glioma; MB, medulloblastoma; SHH, sonic hedgehog; SNV, single nucleotide variant; WES, whole-exome sequencing; WNT, wingless.
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efforts to spare, delay, or reduce CSI, whereas alternative
approaches that mitigate or avoid associated long-term
sequelae are still needed.
The finding that SJMB03 patients with Group 4 tumors tend
to survive longer postrelapse strongly suggests subgroup
determination as a critical component for analyzing patient
outcomes within and across trials for relapsed disease.
Although subgroup and time to relapse appear to be im-
portant factors related to postrelapse survival in our study,
additional molecular and clinical features not explicitly
explored in the current study, such as underlying muta-
tional signatures and genetic predisposition, may influence
biological progression of disease and warrant further
investigation.
Although absolute subgroup stability at relapse has been
reported in patient-matched tumors profiled using the
medulloblastoma-specific expression–based NanoString
assay,13 methylation-based classification of the paired mo-
lecular cohort presented here suggests that a rare pro-
portion of Group 4 tumors switches subgroup affiliation at
relapse to Group 3. These results suggest possible sub-
group plasticity between bulk Group 3 and Group 4 tumors
and warrant further investigation using laboratory models,
particularly to characterize themolecular mechanisms driv-
ing subgroup divergence. Given that subgroup switching
was a rare observational phenomenon in the current study,
genetic drivers underlying this divergence must be ex-
plored further and functionally validated. Overall, subtype
divergence was more common than subgroup divergence.
Associations of subtype divergence with MYC amplification
and chromosome 2p gain (containing the MYCN locus)
suggest the potential influence of these oncogenic tran-
scription factors on subtype identity. Although no specific
molecular feature was identified in cases of divergent
subtype classification for SHH tumors, further exploration
into intrinsic stability of novel subtypes and potential drivers
of such divergence is needed.
The previous literature has described drastic clonal diver-
gence of medulloblastoma at relapse and the emergence of
relapse-specific molecular signatures, including MYC,
MYCN, and TP53 pathway alterations.13,15 In our restricted
analysis of known driver genes, we observed a more variable
degree of conservation than suggested previously. Never-
theless, the previous literature leveraged a variety of mo-
lecular techniques to query specific lesions, such as iFISH
forMYC andMYCN amplifications, which were only used as
a validation in a subset of cases here albeit with high
concordance.15,28 The incidence of such alterations may be
underestimated by methylation array compared to more
sensitive methods, such as iFISH. Also, by leveraging
robust classification methods that can confidently identify a
gamut of CNS tumors, the current study overcomes the
appreciable incidence of high-grade gliomas that might
have confounded previous studies.
Strides toward implementation of novel therapies, including
targeted agents, have largely been based on the molecular
landscape of untreated diagnostic tumors. The current
study reveals primary-specific alterations as a relative mi-
nority, suggesting feasibility of target screening based on
diagnostic tumor specimens. Although relatively infre-
quent, relapse-specific disruptions of DNA repair machin-
ery might represent a viable therapeutic avenue. Similarly,
emergence of relapse-specific alterations in chromatin
modifiers suggests epigenetic dysregulation as a potentially
actionable mechanism underlying therapeutic resistance.
Nevertheless, the degree to which additional molecular
alterations in other unexplored genes, noncoding regions,
or rare subclones may affect target selection must be
evaluated.
Key limitations of the current study stem from the scarcity of
relapse tumor specimens. The paired molecular cohort is
biased toward locally recurrent SHH and nonmetastatic
Group 4 tumors with inclusion of older children and adults
with SHH medulloblastoma. Assembly of the paired mo-
lecular cohort relied heavily on archival FFPE material
without matched germline, thereby limiting mutational
analysis to tumor-only inferences of previously annotated
driver genes and preventing investigation into the role of
germline predisposition. Additional molecular features,
including gene expression and noncoding variants, should
be explored in future studies. The current study of bulk
tumor samples may have also under-called subclonal
variants (, 10%) and is thus not adequately equipped for
analyzing changes in clonal architecture. Single-cell and
deep whole-genome sequencing will provide further in-
sights into mechanisms of tumor evolution and oncogenic
cascades contributing to relapse.
Given that the majority of patients with medulloblastoma
exhibit at least some divergence in molecular features at
relapse, targets should be verified at relapse, particularly in
next-generation clinical trials. Biopsy may represent a safe
and effective alternative to optimize patient selection and
confirm targets for experimental therapies.29 Furthermore,
definitive molecular diagnosis of relapse should be made
given the incidence of other CNS malignancies arising after
medulloblastoma therapy, particularly with increasing time
from initial diagnosis.17,30 Clinical trials of relapsed me-
dulloblastoma paired with confirmatory molecular profiling
are urgently needed to establish standardized protocols for
this deadly disease.
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Montreal, Québec, Canada
41Department of Pathology, Dalhousie University, Halifax, Nova Scotia,
Canada
42Prague Brain Tumor Research Group, Charles University and University
Hospital Motol, Prague, Czech Republic
43Arthur and Sonia Labatt Brain Tumour Research Centre, Hospital for
Sick Children, Toronto, Ontario, Canada
44Division of Pediatric Neurosurgery, Department of Surgery, St. Jude
Children’s Research Hospital, Memphis, TN
45Department of Radiation Oncology, St. Jude Children’s Research
Hospital, Memphis, TN
46Clinical Cooperation Unit Neuropathology, German Cancer Research
Center (DKFZ), Heidelberg, Germany
47Department of Neuropathology, Heidelberg University Hospital,
Heidelberg, Germany
48Division of Haematology/Oncology, Hospital for Sick Children, Toronto,
Ontario, Canada
49Hopp Children’s Cancer Center (KiTZ), Heidelberg, Germany
CORRESPONDING AUTHOR
Paul A. Northcott, PhD, 262 Danny Thomas Place, MS325, Memphis,
TN 38105-3678; e-mail: paul.northcott@stjude.org.
DISCLAIMER
The funders of the study had no role in study design, data collection, data
analysis, data interpretation, or writing of the report. The corresponding
author had full access to all the data and had the final responsibility to
submit for publication.
EQUAL CONTRIBUTION
R.K. and K.S.S. contributed equally to this work. D.T.W.J., A.G., V.R.,
and P.A.N. contributed equally to this work.
SUPPORT
Supported by American Lebanese Syrian Associated Charities, St Jude
Children’s Research Hospital; Alexander and Margaret Stewart Trust
(P.A.N.); American Association for Cancer Research (P.A.N.); St
Baldrick’s Foundation (P.A.N.); Alex’s Lemonade Stand Young
Investigator Award (V.R.); C.R. Younger Foundation (V.R.); Canadian
Institutes of Health Research (V.R.); Nelina’s Hope and Garron Family
Cancer Centre (V.R.).
AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF
INTEREST
Disclosures provided by the authors are available with this article at DOI
https://doi.org/10.1200/JCO.20.01359.
AUTHOR CONTRIBUTIONS
Conception and design: Rahul Kumar, Kyle S. Smith, Giles W. Robinson,
David T. W. Jones, Amar Gajjar, Vijay Ramaswamy, Paul A. Northcott
Financial support:David T. W. Jones, Amar Gajjar, Vijay Ramaswamy, Paul
A. Northcott
Administrative support: Giles W. Robinson, Amar Gajjar, Paul A. Northcott
Provision of study materials or patients: Giles W. Robinson, Brent A. Orr,
Murali Chintagumpala, Daniel C. Bowers, Timothy E. Hassall, Jordan R.
Hansford, Dong Anh Khuong-Quang, John R. Crawford, Anne E. Bendel,
Sridharan Gururangan, Kristin Schroeder, Eric Bouffet, Ute Bartels,
Michael J. Fisher, Richard Cohn, Sonia Partap, Stewart J. Kellie, Geoffrey
McCowage, Arnold C. Paulino, Stefan Rutkowski, Gudrun Fleischhack,
Girish Dhall, Laura J. Klesse, Sarah Leary, Javad Nazarian, Marcel Kool,
14 © 2021 by American Society of Clinical Oncology
Kumar et al
Downloaded from ascopubs.org by 79.168.162.59 on February 5, 2021 from 079.168.162.059
Copyright © 2021 American Society of Clinical Oncology. All rights reserved. 
Pieter Wesseling, Marina Ryzhova, Olga Zheludkova, Andrey V. Golanov,
Roger E. McLendon, Roger J. Packer, Christopher Dunham, Juliette
Hukin, Maryam Fouladi, Claudia C. Faria, Jose Pimentel, Andrew W.
Walter, Nada Jabado, Yoon-Jae Cho, Sebastien Perreault, Sidney E.
Croul, Michal Zapotocky, Cynthia Hawkins, Uri Tabori, Michael D. Taylor,
Stefan M. Pfister, Paul Klimo Jr, Frederick A. Boop, David W. Ellison,
Thomas E. Merchant, Andrey Korshunov, David T. W. Jones, Amar Gajjar,
Vijay Ramaswamy
Collection and assembly of data: Rahul Kumar, Kyle S. Smith, Maximilian
Deng, Giles W. Robinson, Brent A. Orr, Colt Terhune, Anthony P. Y. Liu,
Tong Lin, Catherine A. Billups, Arzu Onar-Thomas, Andrey Korshunov,
David T.W. Jones, Amar Gajjar, Vijay Ramaswamy, Paul A. Northcott
Data analysis and interpretation: Rahul Kumar, Kyle S. Smith, Maximilian
Deng, Giles W. Robinson, Brent A. Orr, Anthony P. Y. Liu, Tong Lin,
Catherine A. Billups, Arzu Onar-Thomas, Andrey Korshunov, David T. W.
Jones, Amar Gajjar, Vijay Ramaswamy, Paul A. Northcott
Manuscript writing: All authors
Final approval of manuscript: All authors
Accountable for all aspects of the work: All authors
REFERENCES
1. Curtin SC, Minino AM, Anderson RN: Declines in cancer death rates among children and adolescents in the United States, 1999-2014. NCHSData Brief:1-8, 2016
2. Ostrom QT, Cioffi G, Gittleman H, et al: CBTRUS statistical report: Primary brain and other central nervous system tumors diagnosed in the United States in
2012-2016. Neuro Oncol 21:v1-v100, 2019
3. Gajjar A, Chintagumpala M, Ashley D, et al: Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with
newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): Long-term results from a prospective, multicentre trial. Lancet Oncol 7:813-820, 2006
4. Tarbell NJ, Friedman H, Polkinghorn WR, et al: High-risk medulloblastoma: A pediatric oncology group randomized trial of chemotherapy before or after
radiation therapy (POG 9031). J Clin Oncol 31:2936-2941, 2013
5. Johnston DL, Keene D, Strother D, et al: Survival following tumor recurrence in children with medulloblastoma. J Pediatr Hematol Oncol 40:e159-e163, 2018
6. Sabel M, Fleischhack G, Tippelt S, et al: Relapse patterns and outcome after relapse in standard risk medulloblastoma: A report from the HIT-SIOP-PNET4
study. J Neurooncol 129:515-524, 2016
7. Koschmann C, Bloom K, Upadhyaya S, et al: Survival after relapse of medulloblastoma. J Pediatr Hematol Oncol 38:269-273, 2016
8. Gajjar A, Mulhern RK, Heideman RL, et al: Medulloblastoma in very young children: Outcome of definitive craniospinal irradiation following incomplete
response to chemotherapy. J Clin Oncol 12:1212-1216, 1994
9. Valteau-Couanet D, Fillipini B, Benhamou E, et al: High-dose busulfan and thiotepa followed by autologous stem cell transplantation (ASCT) in previously
irradiated medulloblastoma patients: High toxicity and lack of efficacy. Bone Marrow Transplant 36:939-945, 2005
10. Grill J, Geoerger B, Gesner L, et al: Phase II study of irinotecan in combination with temozolomide (TEMIRI) in children with recurrent or refractory me-
dulloblastoma: A joint ITCC and SIOPE brain tumor study. Neuro Oncol 15:1236-1243, 2013
11. Gururangan S, Krauser J, Watral MA, et al: Efficacy of high-dose chemotherapy or standard salvage therapy in patients with recurrent medulloblastoma. Neuro
Oncol 10:745-751, 2008
12. Taylor MD, Northcott PA, Korshunov A, et al: Molecular subgroups of medulloblastoma: The current consensus. Acta Neuropathol 123:465-472, 2012
13. Ramaswamy V, Remke M, Bouffet E, et al: Recurrence patterns across medulloblastoma subgroups: An integrated clinical and molecular analysis. Lancet
Oncol 14:1200-1207, 2013
14. Morrissy AS, Garzia L, Shih DJ, et al: Divergent clonal selection dominates medulloblastoma at recurrence. Nature 529:351-357, 2016
15. Hill RM, Kuijper S, Lindsey JC, et al: Combined MYC and P53 defects emerge at medulloblastoma relapse and define rapidly progressive, therapeutically
targetable disease. Cancer Cell 27:72-84, 2015
16. Korshunov A, Okonechnikov K, Sahm F, et al: Molecular progression of SHH-activated medulloblastomas. Acta Neuropathol 138:327-330, 2019
17. Salloum R, Chen Y, Yasui Y, et al: Late morbidity and mortality among medulloblastoma survivors diagnosed across three decades: A report from the childhood
cancer survivor study. J Clin Oncol 37:731-740, 2019
18. Capper D, Jones DTW, Sill M, et al: DNA methylation-based classification of central nervous system tumours. Nature 555:469-474, 2018
19. Northcott PA, Buchhalter I, Morrissy AS, et al: The whole-genome landscape of medulloblastoma subtypes. Nature 547:311-317, 2017
20. Cavalli FMG, Remke M, Rampasek L, et al: Intertumoral heterogeneity within medulloblastoma subgroups. Cancer Cell 31:737-754.e6, 2017
21. Schwalbe EC, Lindsey JC, Nakjang S, et al: Novel molecular subgroups for clinical classification and outcome prediction in childhood medulloblastoma: A
cohort study. Lancet Oncol 18:958-971, 2017
22. Sharma T, Schwalbe EC, Williamson D, et al: Second-generation molecular subgrouping of medulloblastoma: An international meta-analysis of group 3 and
group 4 subtypes. Acta Neuropathol 138:309-326, 2019
23. Robinson GW, Rudneva VA, Buchhalter I, et al: Risk-adapted therapy for young children withmedulloblastoma (SJYC07): Therapeutic andmolecular outcomes
from a multicentre, phase 2 trial. Lancet Oncol 19:768-784, 2018
24. Gajjar A, Robinson GW, Smith KS, et al: Outcomes by clinical and molecular features in children with medulloblastoma treated with risk-adapted therapy:
Results of an international phase III trial (SJMB03). J Clin Oncol 10.1200/JCO.20.01372 [epub ahead of print on January 6, 2021]
25. The St Jude Cloud. https://pecan.stjude.cloud/proteinpaint/study/MB-Relapse
26. Dunkel IJ, Gardner SL, Garvin JH Jr, et al: High-dose carboplatin, thiotepa, and etoposide with autologous stem cell rescue for patients with previously irradiated
recurrent medulloblastoma. Neuro Oncol 12:297-303, 2010
27. Kameda-Smith MM, Wang A, Abdulhadi N, et al: Salvage therapy for childhood medulloblastoma: A single center experience. Can J Neurol Sci 46:403-414, 2019
28. Pickles JC, Stone TJ, Jacques TS: Methylation-based algorithms for diagnosis: Experience from neuro-oncology. J Pathol 250:510-517, 2020
29. Balter-Seri J, Mor C, Shuper A, et al: Cure of recurrent medulloblastoma: The contribution of surgical resection at relapse. Cancer 79:1241-1247, 1997
30. Phi JH, Park AK, Lee S, et al: Genomic analysis reveals secondary glioblastoma after radiotherapy in a subset of recurrent medulloblastomas. Acta Neuropathol
135:939-953, 2018
n n n
Journal of Clinical Oncology 15
Clinico-Molecular Experience With Medulloblastoma Relapse
Downloaded from ascopubs.org by 79.168.162.59 on February 5, 2021 from 079.168.162.059
Copyright © 2021 American Society of Clinical Oncology. All rights reserved. 
AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST
Clinical Outcomes and Patient-Matched Molecular Composition of Relapsed Medulloblastoma
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted.
Relationships are self-held unless noted. I5 Immediate Family Member, Inst5My Institution. Relationships may not relate to the subject matter of this manuscript.
For more information about ASCO’s conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).
Giles W. Robinson
Consulting or Advisory Role: Lilly, Roche/Genentech
Research Funding: Novartis, Genentech/Roche, Novartis
Jordan R. Hansford





Consulting or Advisory Role: Novartis
Research Funding: Roche, Bristol-Myers Squibb
Michael J. Fisher
Honoraria: AstraZeneca
Research Funding: AstraZeneca, Array BioPharma, Exelixis
Travel, Accommodations, Expenses: AstraZeneca, SpringWorks
Sonia Partap
Consulting or Advisory Role: Bayer, Gerson Lehrman Group
Research Funding: Abbvie
Geoffrey McCowage
Consulting or Advisory Role: Biogen
Research Funding: Novartis, Merck
Travel, Accommodations, Expenses: BIOGEN
Arnold C. Paulino
Employment: MD Anderson Cancer Center
Patents, Royalties, Other Intellectual Property: Royalty from Elsevier Inc for
book on PET/CT in Radiotherapy Treatment Planning
Travel, Accommodations, Expenses: University of Southern California
Stefan Rutkowski
Consulting or Advisory Role: Bristol-Myers Squibb GmbH &amp; Co KGaA,
Germany, Celgene, Roche Pharma AG, Grenzach-Wyhlen
Research Funding: Riemser Pharma GmbH, Greifswald, Germany
Laura J. Klesse
Consulting or Advisory Role: AstraZeneca
Travel, Accommodations, Expenses: Springworks, AstraZeneca
Sarah Leary
Research Funding: Blaze Bioscience
Roger E. McLendon
Stock and Other Ownership Interests: Gilead Sciences, NantKwest
Expert Testimony: Johnson & Johnson
Roger J. Packer
Honoraria: Novartis
Consulting or Advisory Role: Novartis, AstraZeneca
Juliette Hukin
Stock and Other Ownership Interests: Abbvie
Maryam Fouladi
Research Funding: PTC therapeutics, Bayer Schering Pharma
Sebastien Perreault
Leadership: Bayer
Stock and Other Ownership Interests: Novocure
Honoraria: Bayer




Consulting or Advisory Role: Bayer
Patents, Royalties, Other Intellectual Property: IP for low grade glioma and
sarcoma fusion panels as well as medulloblastoma subgrouping panel
Stefan M. Pfister
Research Funding: Lilly, Bayer, Roche, PharmaMar, Pfizer
Patents, Royalties, Other Intellectual Property: Patent on utilizing DNA
methylation profiling for tumor classification
Frederick A. Boop
Employment: Semmes Murphey Clinic
David W. Ellison
Patents, Royalties, Other Intellectual Property: Sole inventor of US Patent No.
9,005,907 issued April 14, 2015 “Methods and Compositions for Typing
Molecular Subgroups of Medulloblastoma”, 62627291/S88435 1190US.P1
February 2018 “Epigenetic Histone Regulation Mediated by CXorf67” published
August 2019 as WO 2019/155387
Thomas E. Merchant
Travel, Accommodations, Expenses: Philips Healthcare
Arzu Onar-Thomas
Consulting or Advisory Role: Roche
Research Funding: Novartis, Apexigen, Pfizer, Celgene, Novartis, Merck,
Novocure
Travel, Accommodations, Expenses: Roche
David T. W. Jones
Patents, Royalties, Other Intellectual Property: Patent WO 2013075237 A1,
titled “Mutations of histone proteins associated with proliferative disorders”
Amar Gajjar
Consulting or Advisory Role: Roche/Genentech
Research Funding: Genentech, Kazia Pharmaceutical
Vijay Ramaswamy
Honoraria: AstraZeneca
No other potential conflicts of interest were reported.
© 2021 by American Society of Clinical Oncology
Kumar et al
Downloaded from ascopubs.org by 79.168.162.59 on February 5, 2021 from 079.168.162.059
Copyright © 2021 American Society of Clinical Oncology. All rights reserved. 
APPENDIX
TABLE A1. Demographics and Diagnostic Clinical Characteristics of Relapsed Patients
MB Subgroup


















Female 5 (36%) 8 (31%) 4 (17%) 1 (12%) 10 (50%) 12 (55%) 3 (38%) 1 (50%)
Male 9 (64%) 18 (69%) 20 (83%) 7 (88%) 10 (50%) 10 (45%) 5 (62%) 1 (50%)
Age (IQR) 8.9 (8.4-10.7) 6.4 (4.0-8.5) 7.8 (5.7-10.6) 9.1 (6.3-11.9) 2.0 (1.3-2.5) 2.6 (2.0-2.9) 3.71 (3.0-4.0) 1.1 (1.0-1.2)
M stage
M0 9 (64%) 12 (46%) 10 (42%) 7 (88%) 14 (70%) 11 (50%) 6 (75%) 1 (50%)
M1 0 (0%) 2 (8%) 0 (0%) 0 (0%) 0 (0%) 1 (5%) 0 (0%) 0 (0%)
M2 3 (21%) 0 (0%) 6 (25%) 0 (0%) 1 (5%) 1 (5%) 1 (12%) 0 (0%)
M3 2 (14%) 12 (46%) 8 (33%) 1 (12%) 5 (25%) 9 (41%) 1 (12%) 1 (50%)
Histology
Classic 4 (29%) 15 (58%) 21 (88%) 7 (88%) 2 (10%) 17 (77%) 7 (88%) 2 (100%)
DN 2 (14%) 0 (0%) 0 (0%) 0 (0%) 15 (75%) 0 (0%) 0 (0%) 0 (0%)
LCA 7 (50%) 11 (42%) 3 (12%) 1 (12%) 0 (0%) 5 (23%) 1 (12%) 0 (0%)
MBEN — — — — 3 (15%) 0 (0%) 0 (0%) 0 (0%)
Medullomyoblastoma 1 (7%) 0 (0%) 0 (0%) 0 (0%) — — — —
Resection
GTR 10 (71%) 19 (73%) 16 (67%) 7 (88%) 15 (75%) 15 (68%) 7 (88%) 2 (100%)
NTR 2 (14%) 7 (27%) 7 (29%) 1 (12%) 0 (0%) 4 (18%) 0 (0%) 0 (0%)
STR 2 (14%) 0 (0%) 1 (4%) 0 (0%) 5 (25%) 3 (14%) 1 (12%) 0 (0%)
Postrelapse therapy
Radiation
Yes 4 (29%) 4 (15%) 14 (58%) 3 (38%) 9 (45%) 15 (68%) 6 (75%) 0 (0%)
No 10 (71%) 21 (81%) 10 (42%) 5 (62%) 11 (55%) 7 (32%) 2 (25%) 2 (100%)
Unknown 0 (0%) 1 (4%) 0 (12%) 0 (12%) — — — —
Chemotherapy
Yes 11 (79%) 17 (65%) 21 (88%) 5 (62%) 16 (80%) 12 (55%) 3 (38%) 0 (0%)
No 1 (7%) 3 (12%) 1 (4%) 1 (12%) 4 (20%) 10 (45%) 5 (62%) 2 (100%)
Unknown 2 (14%) 6 (23%) 2 (8%) 2 (25%) — — — —
Abbreviations: DN, desmoplastic nodular; GTR, gross total resection; IQR, interquartile range; LCA, large cell anaplastic; MBEN, medulloblastoma with
extensive nodularity; NTR, near total resection; SHH, sonic hedgehog; STR, subtotal resection.
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Age, mean (SD) 25.0 (11.3) 15.9 (12.2) 5.87 (4.21) 8.75 (3.40) 124
Sex 127
Female 1 (50.0%) 21 (40.4%) 11 (47.8%) 19 (38.0%)
Male 1 (50.0%) 31 (59.6%) 12 (52.2%) 31 (62.0%)
Histology 127
Classic 1 (50.0%) 2 (3.85%) 3 (13.0%) 13 (26.0%)
DNMB 0 (0.00%) 16 (30.8%) 0 (0.00%) 1 (2.00%)
LCA 0 (0.00%) 8 (15.4%) 2 (8.70%) 0 (0.00%)
NOS 1 (50.0%) 26 (50.0%) 18 (78.3%) 36 (72.0%)
M Stage 86
M1 1 (100%) 9 (26.5%) 8 (57.1%) 8 (21.6%)
M0 0 (0.00%) 25 (73.5%) 6 (42.9%) 29 (78.4%)
Resection 79
GTR or NTR 1 (100%) 21 (65.6%) 7 (50.0%) 26 (81.2%)
STR 0 (0.00%) 11 (34.4%) 7 (50.0%) 6 (18.8%)
Relapse pattern 121
Distant 1 (50.0%) 14 (28.6%) 17 (73.9%) 31 (66.0%)
Local 1 (50.0%) 35 (71.4%) 6 (26.1%) 16 (34.0%)
Subgroup conservation 127
Conserved 1 (50.0%) 48 (92.3%) 21 (91.3%) 43 (86.0%)
Divergent 0 (0.00%) 0 (0.00%) 1 (4.35%) 4 (8.00%)
Non-MB subsequent 1 (50.0%) 4 (7.69%) 1 (4.35%) 3 (6.00%)
Therapy (diagnosis)
Chemotherapy 1 (50.0%) 31 (70.5%) 13 (86.7%) 27 (90.0%) 91
Radiotherapy 2 (100%) 31 (70.5%) 7 (46.7%) 27 (90.0%) 91
Therapy (relapse)
Chemotherapy 0 (0.00%) 23 (82.1%) 12 (80.0%) 23 (92.0%) 69
Radiotherapy 1 (100%) 14 (50.0%) 7 (46.7%) 10 (40.0%) 69
NGS data 2 (100%) 26 (50.0%) 11 (47.8%) 25 (50.0%) 64
EFS (SD) 2.79 (1.12) 2.96 (3.49) 1.67 (1.04) 3.42 (2.54) 121
OS (SD) 9.88 (7.25) 5.29 (4.38) 4.08 (3.04) 5.94 (4.30) 97
Abbreviations: DNMB, desmoplastic nodular medulloblastoma; EFS, event-free survival; G3, Group 3; G4, Group 4; GTR, gross total resection; LCA, large
cell anaplastic; MB, medulloblastoma; NGS, next-generation sequencing; NOS, not otherwise specified; NTR, near total resection; OS, overall survival; SHH,
sonic hedgehog; STR, subtotal resection; WNT, wingless.
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